Northwestern Mutual Investment Management Company LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 33.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 465,309 shares of the healthcare product maker’s stock after buying an additional 116,006 shares during the quarter. Northwestern Mutual Investment Management Company LLC’s holdings in Abbott Laboratories were worth $18,291,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Synovus Financial Corp boosted its position in Abbott Laboratories by 4.7% during the second quarter. Synovus Financial Corp now owns 227,271 shares of the healthcare product maker’s stock worth $11,066,000 after purchasing an additional 10,263 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in shares of Abbott Laboratories by 0.7% in the second quarter. Flagship Harbor Advisors LLC now owns 12,341 shares of the healthcare product maker’s stock valued at $600,000 after acquiring an additional 87 shares in the last quarter. Autus Asset Management LLC lifted its position in shares of Abbott Laboratories by 0.6% in the second quarter. Autus Asset Management LLC now owns 124,148 shares of the healthcare product maker’s stock valued at $6,035,000 after acquiring an additional 752 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Abbott Laboratories by 0.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 128,919 shares of the healthcare product maker’s stock valued at $6,267,000 after acquiring an additional 738 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC lifted its position in shares of Abbott Laboratories by 29.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,867 shares of the healthcare product maker’s stock valued at $237,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 69.99% of the company’s stock.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of Abbott Laboratories stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the sale, the insider now directly owns 10,256 shares of the company’s stock, valued at $572,900.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jaime Contreras sold 52,700 shares of Abbott Laboratories stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total value of $2,738,819.00. Following the completion of the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The disclosure for this sale can be found here. In the last three months, insiders have sold 308,939 shares of company stock valued at $16,835,789. 0.76% of the stock is owned by insiders.

Shares of Abbott Laboratories (NYSE:ABT) opened at $56.13 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The stock has a market capitalization of $97,125.53, a price-to-earnings ratio of 23.15, a price-to-earnings-growth ratio of 2.09 and a beta of 1.06. Abbott Laboratories has a one year low of $37.38 and a one year high of $56.69.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.59 earnings per share. equities analysts expect that Abbott Laboratories will post 2.49 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th were paid a dividend of $0.265 per share. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a yield of 1.89%. Abbott Laboratories’s dividend payout ratio (DPR) is 83.47%.

Several equities analysts have recently weighed in on ABT shares. Jefferies Group LLC restated a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 3rd. Stifel Nicolaus raised their target price on Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets restated a “hold” rating and issued a $53.00 target price on shares of Abbott Laboratories in a research report on Friday, September 1st. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Tuesday, October 31st. Finally, Cowen Inc restated a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 17th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $56.81.

WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/northwestern-mutual-investment-management-company-llc-buys-116006-shares-of-abbott-laboratories-abt/1725439.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.